Tarsier Pharma, Ltd, a late-clinical stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of blinding ocular diseases, has appointed Ashley Kline as Chief Commercial Officer, a role that she will hold on a fractional basis as the company completes its late-stage clinical trials.

Experience

Kline brings extensive experience across multiple ophthalmic indications. In her new role, she will lead commercial planning for Tarsier’s pipeline. Before joining Tarsier, Kline held global and U.S. leadership roles at Italy-based Dompé Farmaceutici, where she played a key role in bringing the company’s biologic drug Oxervate to market for a rare eye disease. During her tenure, she successfully led a patient-focused launch that put the drug on the path to blockbuster status.

“I’m excited and honored to join the growing Tarsier Pharma team,” said Kline. “Tarsier has demonstrated a strong commitment to patients battling blinding ocular diseases, including uveitis, a leading cause of blindness in the U.S. I am excited to join Tarsier’s dedicated team and to chart a path that will deliver patient access and commercial excellence for the pipeline of innovative and potentially transformative treatments in development at Tarsier.”

Earlier in her career, Kline served in a variety of leadership and strategic roles in other sectors of ophthalmology, including in uveitis and macular degeneration at companies including Santen, Adverum Biotechnologies, and Genentech.

“We are thrilled to welcome Ashley Kline as our Chief Commercial Officer at this pivotal moment in our company’s growth,” said Daphne Haim-Langford, Ph.D., founder and CEO of Tarsier.  “Ashley brings a wealth of experience in bringing novel therapies to market and building and scaling commercial teams in the U.S.”